Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder

Gigante, Alexandre Dnarte; Lafer, Beny; Yatham, Lakshmi N.
May 2012
CNS Drugs;2012, Vol. 26 Issue 5, p403
Academic Journal
Depot antipsychotics have been used as a strategy to reduce non-adherence to medications in schizophrenia and bipolar disorder (BD). This article reviews the literature on the efficacy and safety of first- and second-generation depot antipsychotics (FGDA and SGDA, respectively) for the maintenance treat-ment of BD. Although FGDA have been studied in BD, they have not been approved for use in this disease. Among the SGDA, only depot risperidone has been studied and approved for the maintenance treatment of BD. We found eight studies on FGDA (three on flupenthixol, two on depot halo-peridol, one on fluphenazine and flupenthixol, two on a mix of diverse anti-psychotics) and ten studies on SGDA (all on depot risperidone). Differences in efficacy and safety were found between the two classes of depot antipsy-chotics. Although FGDA may be effective in reducing manic relapses, they possibly increase the risk of worsening depression. Depot risperidone is effective as a maintenance treatment in BD with effect noted predominantly for preventing mania. However, no worsening in depression was observed. Depot risperidone also is better tolerated than FGDA, mainly in relation to extrapyramidal symptoms. Studies with the new depot antipsychotics, olan-zapine pamoate and paliperidone palmitate, are needed in BD patients. Further, there is currently little information on the metabolic changes (apart from bodyweight gain) that may occur with the use of depot risperidone in patients with bipolar disorder, and this issue needs further investigation.


Related Articles

  • The genotoxic potentials of some atypical antipsychotic drugs on human lymphocytes. Togar, Başak; Turkez, Hasan; Tatar, Abdulgani; Kırkpınar, Ismet; Hacımuftuoglu, Ahmet; Geyikoglu, Fatime; Keles, M Sait; Dirican, Ebubekir // Toxicology & Industrial Health;May2012, Vol. 28 Issue 4, p327 

    Olanzapine (OLZ), risperidone (RPD) and quetiapine (QTP) are atypical antipsychotic drugs and are commonly used for the treatments of schizophrenia and bipolar disorders. However, recent reports indicated that these drugs could exhibit toxic effects on nervous and cardiovascular systems. To our...

  • Risperidone treatment of bipolar disorder. McIntyre, Roger; Hasey, Gary; Patelis-Siotis, Irene; Jones, Barry D.; McIntyre, R; Young, L T; Hasey, G; Patelis-Siotis, I; Jones, B D // Canadian Journal of Psychiatry;Feb1997, Vol. 42 Issue 1, p88 

    A letter to the editor is presented about a study on whether risperidone treatment can reduce mood symptoms in patients with bipolar disorder.

  • The promise of new drugs for schizophrenia treatment. Tamminga, C. A.; Tamminga, Ca // Canadian Journal of Psychiatry;Apr1997, Vol. 42 Issue 3, p265 

    Objective: To present aspects of preclinical and clinical pharmacology of new antipsychotic drugs and to emphasize those preclinical drug characteristics which might predict desirable clinical actions.Method: Review of the relevant literature and publicly presented...

  • Economic evaluations of olanzapine and risperidone. Shaw, James W. // American Journal of Health-System Pharmacy;7/15/2002, Vol. 59 Issue 14, p1366 

    Presents an economic analysis comparing olanzapine and risperidone for treating schizophrenia. Overview of the disease; Costs of schizophrenia; Methods of economic evaluation; Results of randomized clinical trials.

  • Medication Treatment Patterns following Initiation on Olanzapine versus Risperidone: A Retrospective Analysis. Zhao, Z.; Tunis, S.L.; Lage, M.J. // Clinical Drug Investigation;2002, Vol. 22 Issue 11, p741 

    Objective: To compare medication treatment patterns for patients with schizophrenia following initiation on olanzapine versus risperidone. Methods: Retrospective analysis of a large, geographically diverse claims database of insured individuals identified 670 enrollees who: (1) were diagnosed...

  • A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia. Fitzgerald, Paul B.; Brown, Timothy L.; Daskalakis, Jeff Z.; Kulkarni, J. // Psychopharmacology;2002, Vol. 162 Issue 1, p74 

    Rationale: There has been a progressive increase in interest in the functioning of the main inhibitory and excitatory neurotransmitters in the pathophysiology of schizophrenia. Limited information is available as to how these neurotransmitters are affected by commonly prescribed antipsychotic...

  • Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. Edgell, E.T.; Andersen, S.W.; Johnstone, B.M.; Dulisse, B.; Revicki, D.; Breier, A. // PharmacoEconomics;2000, Vol. 18 Issue 6, p567 

    Objective: To compare the clinical and economic outcomes associated with olanzapine and risperidone treatment for schizophrenia.Design and Setting: An international, multicentre, double-blind, prospective study. To facilitate economic comparisons, our sample was...

  • First antipsychotic medication endorsed for children and teens.  // Contemporary Pediatrics;Sep2007, Vol. 24 Issue 9, p23 

    The article reports on the approval of risperidone by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adolescents ages 13 to 17 on August 22, 2007. The drug can also be used as a short-term treatment of manic or mixed episodes of bipolar I disorder in children...

  • FORMULATION, DESIGN AND OPTIMIZATION OF FAST DISSOLVING TABLET OF OLANZAPINE BY SIMPLEX LATTICE DESIGN. Patel, P. B.; Rao, B. P.; Goli, D.; Tank, N. A. // Pharma Science Monitor;Oct2012, Vol. 3 Issue 4, p1980 

    The Anti-psychotic agent used for the present study is Olanzapine. Olanzapine is an atypical antipsychotic drug of the thienobenzodiazepine class for treatment of schizophrenia and to control manic episodes of bipolar disorder. Olanzapine is well absorbed from GIT and its half-life ranges from...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics